SecBot SecBot
DEFA14A ·Filed Nov 9, 2026

LSTA

LISATA THERAPEUTICS, INC.
NEUTRAL
Impact 6/10
Horizondays Processed12d 14h ago SEC0001140361-26-042820
Proxy solicitation materials
Actionable Insight • Neutral

The November 30 reconvened vote is the binary event for Lisata's post-merger survival. Monitor proxy solicitation updates and any Nasdaq listing application approval before that date. If the Conversion Proposal fails, the company faces cash settlement obligations and potential delisting.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$1.02
T+0 close · Nov 9, 2026 · via day close
Latest settled
+1.96%
T+5 · $1.04 · next T+20 in 17d
Vs SPY
+4.29%
α at T+5
Latest observation
−12.23%
T+8 · FF3 residual α
  1. T+0 · Nov 10 $1.02entry
  2. T+1 · 11d ago +17.65%α +16.33% · $1.20
  3. T+5 · 5d ago +1.96%α +4.29% · $1.04
  4. T+8 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lisata Therapeutics adjourned its 2026 annual meeting solely on Proposal No. 3 (conversion of Series C Preferred Stock, which would represent >20% of outstanding shares and result in a change of control) to November 30, 2026, to allow more time for proxy solicitation and Nasdaq listing application approval. The board continues to unanimously recommend a FOR vote. All other proposals were voted on and results will be reported in a separate 8-K.

Key Financial Metrics

Vote
shareholder proposal
Meeting
2026-11-30

Key Facts

  • Annual meeting convened November 9, 2026; votes taken on Proposals 1, 2, 4, 5, 6, 7, and 8.
  • Meeting adjourned solely on Proposal No. 3 (Conversion Proposal) to allow more time for proxy solicitation and Nasdaq listing application approval.
  • Reconvened meeting set for November 30, 2026 at 11:00 a.m. ET, virtual only.
  • Conversion Proposal seeks approval of common stock issuance upon conversion of Series C Preferred Stock, representing >20% of outstanding shares and resulting in a change of control under Nasdaq rules.
  • Record date remains October 9, 2026; previously submitted proxies will be voted as instructed unless revoked.
  • Board unanimously recommends a FOR vote on the Conversion Proposal.
  • Failure to pass could trigger cash settlement obligations for Series C Preferred holders and risk Nasdaq delisting (per prior DEF 14A summary).

Financial Impact

Conversion of Series C Preferred would dilute legacy stockholders to approximately 2.4% ownership (per prior DEF 14A summary); failure could trigger cash settlement obligations.

dilutionownershiplisting status

Risk Factors

  • Conversion Proposal may not pass, triggering cash settlement obligations for Series C Preferred holders.
  • Nasdaq initial listing application approval is pending; failure could lead to delisting.
  • Legacy stockholders face dilution to approximately 2.4% ownership if proposal passes.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001140361-26-042820
Document: 0001140361-26-042820-index-headers.html0001140361-26-042820
Document: 0001140361-26-042820-index.html0001140361-26-042820
Document: 0001140361-26-042820.txt0001140361-26-042820

Track record

21 reports on LSTA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +54.62% at T+60 after the Jun 9, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 19, 20262d ago S-3/A Bearish 6/10 Entry $0.9507 settles Feb 19
  2. Nov 19, 20262d ago 8-K/A Neutral 3/10 Entry $0.9507 settles Feb 19
  3. Nov 19, 20262d ago 8-K Bearish 5/10 Entry $0.9100 settles Feb 18
  4. Nov 19, 20262d ago Press Release Neutral 4/10 Entry $0.9100 settles Feb 18
  5. Nov 12, 20269d ago S-3 Bearish 6/10 Entry $1.21 settles Feb 11
  6. Nov 12, 202610d ago 8-K/A Neutral 4/10 Entry $1.28 settles Feb 10
  7. Nov 9, 202612d ago DEFA14A Neutral 6/10 Viewing Entry $1.02 settles Feb 8
  8. Nov 9, 202612d ago 8-K Neutral 4/10 Entry $1.02 settles Feb 8
  9. Oct 19, 20264w ago DEF 14A Bearish 7/10 Entry $1.00 settles Jan 14
  10. Oct 14, 20265w ago 8-K Neutral 2/10 Entry $1.07 settles Jan 12
Showing 10 of 21

US Market Status

Market Closed · Opens Mon (26h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026